Reflections on Governance Models for the Clinical Translation of Stem Cells

Lo B. Kriegstein A. Grady D. , “Clinical Trials in Stem Cell Transplantation: Guidelines for Scientific and Ethical Review,” Clinical Trials 5, no. 5 (2008): 517–522; Lo B. , “Case-Based Reasoning in Stem Cell Clinical Trials: The Case of Parkinson Disease,” Journal of Law, Medicine & Ethics 38, no. 2 (2010); Magnus D. , “Translating Stem Cell Research: Challenges at the Research Frontier,” Journal of Law, Medicine & Ethics 38, no. 2 (2010).

National Academy of Sciences, Guidelines for Human Embryonic Stem Cell Research (Washington, D.C.: National Academies Press, 2005).

National Academy of Sciences, 2007 Amendments to the National Academies' Guidelines for Human Embryonic Stem Cell Research (Washington, D.C.: National Academies Press, 2007).

National Academy of Sciences, 2008 Amendments to the National Academies' Guidelines for Human Embryonic Stem Cell Research (Washington, D.C.: National Academies Press, 2008).

International Society for Stem Cell Research, Guidelines for the Conduct of Human Embryonic Stem Cell Research, 2006, available at <http://www.isscr.org/guidelines/ISS-CRhESCguidelines2006.pdf> (last visited April 7, 2010).

See International Society for Stem Cell Research, “Guidelines for the Conduct of Human Embryonic Stem Cell Research,” available at <http://www.isscr.org/guidelines/index.htm> (last visited April 7, 2010).

International Society for Stem Cell Research, Guidelines for the Clinical Translation of Stem Cells, 2008, available at <http://www.isscr.org/clinical_trans/pdfs/ISSCRGLClinicalTrans.pdf> (last visited April 7, 2010).

Hyun I. Lindvall O. Ahrlund-Richter L. Cattaneo E. Cavazzana-Calvo M. Cossu G. De Luca M. Fox I. J. Gerstle C. Goldstein R.A. Hermeren G. High K. A. Kim H. O. Lee H.P. Levy-Lahad E. Li L. Lo B. Marshak D. R. McNab A. Munsie M. Nakauchi H. Rao M. Rooke H. M. Valles C. S. Srivastava A. Sugarman J. Taylor P. L. Veiga A. Wong A. L. Zoloth L. Daley G. Q. , “New ISSCR Guidelines Underscore Major Principles for Responsible Translational Stem Cell Research,” Cell Stem Cell 3, no. 6 (2008): 607–609.

See Lo , supra note 1.

Id., at 517.

Mathews D. J. Sugarman J. Bok H. Blass D. M. Coyle J.T. Duggan P. Finkle J. Greely H. T. Hillis A. Hoke A. Johnson R. Johnston M. Kahn J. Kerr D. Kurtzberg J. Liao S. M. McDonald J. W. McKhann G. Nelson K. B. Rao M. Regenberg A. Siegel A. W. Smith K. Solter D. Song H. Vescovi A Young W. Gearhart J. D. Faden R. , “Cell-Based Interventions for Neurologic Conditions: Ethical Challenges for Early Human Trials,” Neurology 71, no. 4 (2008): 1–6.

Sugarman J. McCrory D. C. Powell D. Krasny A. Adams B. Ball E. Cassell C. , “Empirical Research on Informed Consent,” Hastings Center Report 29, no. 1 (1999): S1–S42.

Sugarman J. Kass N. E. Goodman S. N. Perentesis P. Fernandes P. Faden R. R. , “What Patients Say About Medical Research,” IRB 20, no. 4 (1998): 1–7.

King N. M. P. , “Rewriting the ‘Points to Consider’: The Ethical Impact of Guidance Document Language,” Human Gene Therapy 10, no. 1 (1999): 133–139.

Sugarman J. Lavori P. W. Boeger M. Cain C. Edson R. Morrison V. Yeh S. S. , “Evaluating the Quality of Informed Consent,” Clinical Trials 2, no. 1 (2005): 1–8.

Taylor H. A. Chaisson L. Sugarman J. , “Enhancing Communication Among Data Monitoring Committees and Institutional Review Boards,” Clinical Trials 5, no. 3 (2008): 277–282.

Zettler P. Wolf L. Lo B. , “Establishing Procedures for Institutional Oversight of Stem Cell Research,” Academic Medicine 82, no. 1 (2007): 6–10; Sugarman J. Siegel A. , “How to Determine Whether Existing Human Embryonic Stem Cell Lines Can Be Used Ethically,” Cell Stem Cell 3, no. 3 (2008): 238–239; Sugarman J. Siegel A. W. , “When Embryonic Stem Cell Lines Fail to Meet Consent Standards,” Science 322, no. 5900 (2008): 379.

Levine C. Faden R. Grady C. Hammerschmidt D. Eckenwiler L. , and J. Sugarman, on behalf of the Consortium to Examine Clinical Research Ethics, “‘Special Scrutiny’: A Targeted Form of Research Protocol Review,” Annals of Internal Medicine 140, no. 3 (2004): 220–223.

See Lo supra note 1.

Office of Biological Activities, National Institutes of Health. Appendix L, available at <http://oba.od.nih.gov/oba/rac/guidelines_02/Appendix_L.htm> (last visited April 7, 2010).

National Institutes of Health (NIH), Gene Therapy Policy Conference: Prenatal Gene Transfer: Scientific, Medical, and Ethical Issues, January 7–8, 1999, available at <http://oba.od.nih.gov/oba/rac/gtpcconc.pdf> (last visited April 7, 2010); Sugarman J. , “Ethical Considerations in Leaping from Bench to Bedside,” Science 285, no. 5436 (1999): 2071–2072.

Recombinant DNA Advisory Committee, RAC Statement, March 11, 1999, available at <http://oba.od.nih.gov/oba/rac/racinutero.pdf> (last visited April 7, 2010).

Lau D. Ogbogu U. Taylor B. Stafinski T. Menon D. Caulfield T. , “Stem Cell Clinics Online: The Direct-to-Consumer Portrayal of Stem Cell Medicine,” Cell Stem Cell 3, no. 6 (2008): 591–594; Kiatpongsan S. Sipp D. , “Monitoring and Regulating Offshore Stem Cell Clinics,” Science 323, no. 5921 (2009): 1564–1565.

See ISSCR, supra note 7.

Id.

Id.; see Lo , supra note 1.

Id. (ISSCR).